Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cetuximab Added to Capecitabine, Oxaliplatin and Bevacizumab in Patients With Previously Untreated Advanced Colorectal Carcinoma, a Randomised Phase III Study

NCT00208546 is registered in ClinicalTrials.gov with Dutch Colorectal Cancer Group as lead sponsor.

NCT NCT00208546
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00208546 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cetuximab Added to Capecitabine, Oxaliplatin and Bevacizumab in Patients With Previously Untreated Advanced Colorectal Carcinoma, a Randomised Phase III Study
Lead sponsor
Dutch Colorectal Cancer Group
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2005
Completion date
December 31, 2009
Enrollment
750 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer